Piramal Group
This sponsor has funded 2 studies across 5 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 12145 | Finalised | A prospective observational study to assess effectiveness of the training and risk minimisation measures recommended for the usage of the diagnostic... | No | No |
| 13366 | Finalised | Pattern of use, safety and tolerability of the diagnostic agent NeuraCeqTM in European clinical practice: A cross-sectional, retrospective,... | No | No |
PAS by Risk Management Plan (RMP) requirement
Piramal Group
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Piramal Group
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Piramal Group
5 Study countries specified are the following:
- France
- Germany
- Italy
- Spain
- United Kingdom